Human Vaccines & Immunotherapeutics (Dec 2024)

CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy

  • Yasemin Ahrberg,
  • Julia Dallmann,
  • Janina Freitag,
  • Abdulrizak Hassan,
  • Christina Jung,
  • Johanna Kiefer,
  • Anindhita Meena Muralidharan,
  • Matthias Peter,
  • Jan D. Beck

DOI
https://doi.org/10.1080/21645515.2024.2381925
Journal volume & issue
Vol. 20, no. 1

Abstract

Read online

The 21st Association for Cancer Immunotherapy (CIMT) Annual Meeting took place from May 15th to May 17th in Mainz, Germany, and was attended by a total of 855 academic and clinical professionals hailing from 33 different countries. The conference served as a platform for these experts to convene and discuss the latest breakthroughs in cancer immunology and immunotherapy research. Dedicated sessions covering advancements in artificial intelligence tools for cancer immunotherapy research, as well as the landscape of cancer care and cancer immunotherapy trials on the African continent, prompted lively and informative discussions among the attendees. This report aims to provide an overview of the most noteworthy highlights and key takeaways from CIMT2024.

Keywords